Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Curly Morris, Christian Chabannon, Tamas Masszi, Nigel Russell, Hareth Nahi, Guido Kobbe, Marta Krejci, Holger W. Auner, David Pohlreich, Patrick Hayden, Grzegorz W. Basak, Stig Lenhoff, Nicolaas Schaap, Anja van Biezen, Cora Knol, Simona Iacobelli, Qianying Liu, Marina Celanovic, Laurent Garderet, Nicolaus Kröger

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.

Original languageEnglish
Pages (from-to)356-366
Number of pages11
JournalBone Marrow Transplantation
Volume55
Issue number2
DOIs
Publication statusPublished - Feb 1 2020

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor'. Together they form a unique fingerprint.

  • Cite this

    Morris, C., Chabannon, C., Masszi, T., Russell, N., Nahi, H., Kobbe, G., Krejci, M., Auner, H. W., Pohlreich, D., Hayden, P., Basak, G. W., Lenhoff, S., Schaap, N., van Biezen, A., Knol, C., Iacobelli, S., Liu, Q., Celanovic, M., Garderet, L., & Kröger, N. (2020). Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplantation, 55(2), 356-366. https://doi.org/10.1038/s41409-019-0676-0